Currently out of the existing stock ratings of Ed Arce, 552 are a BUY (86.66%), 82 are a HOLD (12.87%), 3 are a SELL (0.47%).

Ed Arce

Work Performance Price Targets & Ratings Chart

Analyst Ed Arce, currently employed at WESTPARK, carries an average stock price target met ratio of 45.02% that have a potential upside of 40.79% achieved within 261 days.

Ed Arce’s has documented 1,152 price targets and ratings displayed on 58 stocks. The coverage is on Healthcare, Basic Materials, Financial Services, Energy, Industrials sectors.

Most recent stock forecast was given on AKBA, Akebia Ther at 07-Sep-2026.

Wall Street Analyst Ed Arce

Analyst best performing recommendations are on ACR (ACRES COMMERCIAL REALTY CORP).
The best stock recommendation documented was for AKRO (AKERO THERAPEUTICS) at 1/16/2025. The price target of $50 was fulfilled within 11 days with a profit of $25.99 (108.25%) receiving and performance score of 98.41.

Average potential price target upside

of $516.67 (97.12%) on CNAT (CONATUS PHARMACEUTICALS).
of $91.29 (48.57%) on ALB (ALBEMARLE CORP).
of $84.9 (58.84%) on MDGL (MADRIGAL PHARMACEUTICALS).

GNFT Genfit PRTK Paratek Pharmaceuticals AKBA Akebia Ther ALBO Albireo Pharma AUPH Aurinia Pharmaceuticals AXLA Axcella Health DRNA Dicerna Pharmaceuticals MIRM Mirum Pharmaceuticals PLRX Pliant Therapeutics AKRO Akero Therapeutics ETNB 89bio ETTX Entasis Therapeutics Holdings IVA Inventiva Sa TVTX Travere Therapeutics VERA Vera Therapeutics ICPT Intercept Pharmaceuticals UNCY Unicycive Therapeutics CDTX Cidara Therapeutics TERN Terns Pharmaceuticals ABUS Arbutus Biopharma Corp ACXP Acurx Pharmaceuticals LLC ARCT Arcturus Therapeutics Holdings ASMB Assembly Biosciences CBAY Cymabay Therapeu DRRX Durect GALT Galectin Therapeutics KDNY Chinook Therapeutics ACRX AcelRx Pharmaceuticals ARDX Ardelyx ENTA Enanta Pharmaceuticals MDGL Madrigal Pharmaceuticals RARE Ultragenyx SYBX Synlogic AKAO Achaogen CNAT Conatus Pharmaceuticals ITRM Iterum Therapeutics PLC MLNT Melinta Therapeutics NBRV Nabriva Therapeutics AG TTPH Tetraphase Pharmaceuticals TRVN Trevena GLMD Galmed Pharmaceuticals Ltd ALGS Aligos Therapeutics NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares SGMT Sagimet Biosciences Series A Common Stock COLL Collegium Pharmaceutical GEMP Gemphire Therapeutics NRBO Neurobo Pharmaceuticals ONVO Organovo Holdings RLYP Relypsa SMMT Summit Therapeutics PLC SPRO Spero Therapeutics ACR Acres Commercial Realty Corp AKR Acadia Realty Trust ALB Albemarle Corp AX Axos Financial ET Energy Transfer LP ETN Eaton PLC KD Kyndryl Holdings

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Brandon Folkes (HC WAINWRIGHT)

Buy Since 19-Aug-2025

$1.03 (17.25%)

1 years 3 days ago
(24-Sep-2025)

0/2 (0%)

$3.37 (92.84%)

Please subscribe to see extended stock data

Ed Arce (HCWAINWRIGHT)

Buy Since 17-Apr-2023

$13

$7.03 (117.76%)

1 years 7 months 20 days ago
(07-Feb-2025)

0/15 (0%)

$9.09 (232.48%)

Please subscribe to see extended stock data

Thomas Smith (LEERINK)

Buy Since 11-Apr-2022

$10

$4.03 (67.50%)

$10

3 years 5 months 8 days ago
(19-Apr-2023)

0/2 (0%)

$6.2 (163.16%)

Please subscribe to see extended stock data

Geoff Meacham (CITI)

Sell Since 05-Jan-2021

$-0.97 (-16.25%)

$55

5 years 8 months 22 days ago
(05-Jan-2021)

1/2 (50%)

$-0.02 (-0.40%)

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Ed Arce most bullish on?

Potential upside of $3.47 has been obtained for AKBA (AKEBIA THER)

What Year was the first public recommendation made by Ed Arce?

On 2015